CytoDyn Inc.
CytoDyn Inc. (CYDY) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for CytoDyn Inc. (CYDY), featuring income statements, balance sheets, and cash flow data.
CytoDyn Inc. (CYDY) Income Statement & Financial Overview
Access detailed annual and quarterly income data for CytoDyn Inc. CYDY financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $50000.00 | $0.00 |
| Cost of Revenue | $0.00 | $5000.00 | $4000.00 | $7000.00 |
| Gross Profit | $0.00 | -$5000.00 | $46000.00 | -$7000.00 |
| Gross Profit Ratio | $0.00 | $0.92 | ||
| R&D Expenses | $1.41M | -$24.05M | $3.60M | $650000.00 |
| SG&A Expenses | $2.29M | $1.60M | $3.03M | $2.76M |
| Operating Expenses | $3.71M | -$22.44M | $6.63M | $3.41M |
| Total Costs & Expenses | $3.71M | -$22.44M | $6.63M | $3.41M |
| Interest Income | $142000.00 | $126000.00 | $0.00 | $0.00 |
| Interest Expense | $1.27M | $1.29M | $954000.00 | $2.65M |
| Depreciation & Amortization | $4000.00 | $5000.00 | $4000.00 | $7000.00 |
| EBITDA | -$3.49M | $20.54M | -$13.92M | -$9.27M |
| EBITDA Ratio | -$278.32 | |||
| Operating Income | -$3.71M | $22.44M | -$6.63M | -$3.41M |
| Operating Income Ratio | -$132.68 | |||
| Other Income/Expenses (Net) | -$1.06M | -$3.21M | -$10.15M | -$8.51M |
| Income Before Tax | -$4.77M | $19.23M | -$16.79M | -$11.92M |
| Income Before Tax Ratio | -$335.74 | |||
| Income Tax Expense | $0.00 | $0.00 | -$24.80M | $11.92M |
| Net Income | -$4.77M | $19.23M | -$16.79M | -$11.92M |
| Net Income Ratio | -$335.74 | |||
| EPS | -$0.004 | $0.02 | -$0.02 | -$0.01 |
| Diluted EPS | -$0.004 | $0.02 | -$0.02 | -$0.01 |
| Weighted Avg Shares Outstanding | $1.22B | $1.14B | $1.000B | $982.21M |
| Weighted Avg Shares Outstanding (Diluted) | $1.22B | $1.20B | $1.000B | $982.21M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q3 2024 to $0.00 in Q2 2025. Gross profit remained healthy with margins at N/A in Q2 2025 compared to N/A in Q3 2024. Operating income hit -$3.71M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.49M. Net income dropped to -$4.77M, while earnings per share reached -$0.004. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan